RE:RE:$$ ; Sixty days ago, I was in the "testing is limited play" camp. Seeing what is going on here in the U.S. with Delta and the new mutations popping up weekly, I'm now in the "testing is here to stay" camp. That said, the addition of a medical vertical was a brilliant move, assuming their follow-through execution is spot-on.
With the medical vertical via MediCall plus whatever we are doing with Perspectum added on to the existing infrastructure, I'd say your $2 projection is on the "very conservative" side.
SeniorC wrote: If you consider the IT Industry S/P the share price actually could be at 0,24$. Any announcement should move the needle really fast because we sit on a huge "insurance policy" called COVID testing. If the market decides to take the testing revenues into account in the share price (not the case for now) ant they do it at an S/P ratio of 10 which Is more adequate for the testing part the share price would be around 1,55$ right now. Taking all the revenues with an S/P ratio of IT industry (not adequate for me) then we speak of about 4,75$. My point is that we have more and more indications testing will stay so testing may start pressure the price toward new highs. For sure, any AI PR supported by that possible 1,55$ will have a strong and rapid impact to the maximum S/P of the industry. In conclusion I strongly believe all the propellers are fully loaded ready to bring us to impressive numbers. I still believe we could be at around 2,00$ in a year from now... DYODD